What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “IBI3032: Method of administration: oral, fasted administration.”In the company’s words, NCT07120425 on ClinicalTrials.gov
- Tested for
- Overweight or Obesity
- Main trialPhase 1
- “This is a randomized, double-blind, placebo-controlled Phase I clinical study evaluating the safety, tolerability, and PK of a single dose of IBI3032 in healthy participants. This is a single ascending dose (SAD) study. Approximately 32 healthy participants are expected to be enrolled in this study. The screening period is 4 weeks. Eligible participants will be divided into 4 cohorts. Each cohort consisted of 8 healthy participants who will be randomized in a 6:2 ratio to receive a single dose of IBI3032 or placebo. The safety follow-up period is 15 days. This study is for research purposes…”In the company’s words, NCT07120425 on ClinicalTrials.gov
Other drugs for Overweight or Obesity
- RetatrutideEli Lilly · Phase 3
- TradipitantVanda Pharmaceuticals · Phase 3
- LiraglutideNovo Nordisk · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- HRS-7535Hengrui · Kailera · Phase 3
- IN-B00009HK inno.N · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 13 Nov 2025 | A Study of IBI3032 in Healthy Participants | |
| Phase 1Active, not recruiting | 24 Dec 2025 | A Study of IBI3032 in Chinese Participants With Overweight or Obesity | |
| Phase 1Completed | 6 Aug 2026 | A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026